Inhibitron F (Omeprazole)
Active Ingredient: Omeprazole
Dosage: 40 mg
Route of Administration: Oral
Dosage Form: Capsules
Quantity per package: 7 capsules per pack
Inhibitron F is used to treat acid-peptic disorders, such as peptic ulcer associated with other medications, gastric and duodenal ulcer, gastroesophageal reflux esophagitis, gastropathy caused by non-steroidal anti-inflammatories, Zollinger-Ellison syndrome, prophylaxis of aspiration pneumonia. The drug is also effective in cases of gastric or duodenal ulcer and reflux esophagitis.
Inhibitron F is out of stock at the moment but you can order its complete analog on this page.
Inhibitron F is indicated for the short-term and long-term treatment of patients with acid-peptic disorders such as: GERD (gastroesophageal reflux disease) symptomatic associated or not with hiatal hernia, duodenal ulcer, gastric ulcer, Mendelson syndrome (pneumonia by aspiration), NSAID gastropathy, eradication of Helicobacter pylori in association with other medications, Zollinger-Ellison syndrome and in those cases of gastric or duodenal ulcers and reflux esophagitis refractory to conventional treatments with other antisecretory drugs (receptor antagonists H2).
Dosage and administration
For oral use.
Severe reflux esophagitis: 1 capsule of 40 mg once daily, for 8 weeks. In patients whose mucous membranes have not fully healed after this initial period, they will usually do so during an additional four-week period of treatment. In case of scar reflux esophagitis, if necessary, Inhibitron F 40 mg is administered once daily.
Gastric or duodenal ulcer: 1 capsule of 40 mg once daily, for 2 or 3 consecutive weeks. In patients with ulcers refractory to other treatment regimens, healing is obtained in most cases with a dose of 40 mg once daily for 8 consecutive weeks.
Eradication of Helicobacter pylori:
- Triple therapy: Inhibitron F 40mg once a day + amoxicillin 500 mg three times a day + metronidazole 400 mg three times a day, for a week;
- Double therapy: 40-80 mg per day + amoxicillin 500 mg three times a day for 2 weeks, or 40 mg once a day + clarithromycin 500 mg three times a day for 2 weeks.
Any of the schemes can be repeated if the infection persists a month after treatment.
Zollinger-Ellison syndrome: The initial dose is 60 mg, once a day. The dose should be adjusted individually and treatment should continue as long as the clinical indication exists. Most patients are controlled with doses of 20 to 120 mg daily. If the dose exceeds 80 mg daily, it should be divided and administered in two doses per day.
Acid aspiration prophylaxis: 40 mg the night before surgery and 40 mg before surgery.
Renal impairment and the elderly: In elderly patients or those with impaired renal or hepatic function, no dosage adjustments are necessary.
- Hypersensitivity to omeprazole, benzimidazoles;
- Use with nelfinavir.
Generally, the drug is well tolerated and has a broad safety profile. At the recommended doses and therapeutic scheme, mild intensity reactions have been reported in some cases: pruritus, rash, arthralgia, myalgia, headache, dizziness, vertigo, nausea, drowsiness, insomnia, diarrhea, constipation and flatulence.
In very rare cases, the drug caused photosensitivity, erythema multiforme, alopecia, arthralgia, muscle weakness, myalgia, paraesthesia, occasionally reversible mental confusion, agitation, depression, hallucination, abdominal pain, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, increased liver enzymes, encephalopathy in patients with preexisting severe liver disease, hepatitis with or without jaundice, liver failure, gynecomastia, leukopenia, agranulocytosis and pancytopenia; general malaise, hypersensitivity reactions, angioedema, fever, bronchospasm, interstitial nephritis, anaphylactic shock, diaphoresis, peripheral edema, blurred vision and taste disturbance.
Rare cases of overdose with Inhibitron F have been reported. Transient symptoms have been reported: nausea, dizziness, abdominal pain, diarrhea, headache. Isolated cases of overdose were accompanied by apathy, depression and confusion.
There is no specific treatment, but if required, symptomatic and supportive treatment is recommended.
This drug may delay the elimination of diazepam, phenytoin, warfarin and other drugs that are metabolized by oxidation in the liver by the CYP2C19 isoenzyme. Do not use this drug with nelfinavir. It is recommended to monitor patients treated simultaneously with phenytoin.